Biotechnology

Mereo Biopharma

Mereo Biopharma released FY2025 earnings on March 19 (EST), actual revenue USD 500 K (forecast USD 7.574 M), actual EPS USD -0.2626 (forecast USD -0.0596)

Mereo Biopharma released FY2025 Q4 earnings on March 19 (EST), actual revenue USD 0 (forecast USD 7.133 M), actual EPS USD -0.0459 (forecast USD -0.0112)

Mereo BioPharma Extends Cash Reserves and Analyzes Phase 3 Study Data

Leerink Partners analyst reiterates buy rating on Mereo Biopharma stock

Cory Jubinville Maintains Mereo Biopharma Group Plc Buy Rating with $9 Price Target

Gil Blum Maintains 'Buy' Rating on Mereo Biopharma with $5.00 Price Target

Mereo Biopharma released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 4.971M), actual EPS USD -0.0439 (forecast USD -0.0053)

Mereo Biopharma released FY2025 9 Months earnings on November 10 (EST), actual revenue USD 500K, actual EPS USD -0.2235

Mereo Biopharma released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 500K (forecast USD 0), actual EPS USD -0.0914 (forecast USD -0.0118)

Mereo Biopharma released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 500K, actual EPS USD -0.1731 (forecast EPS USD -0.0202)

Needham Downgrades Mereo BioPharma's Target Price to $5.00

Mereo BioPharma Group's Financial Status: Rising Cash Burn but Overall Manageable

Mereo Biopharma released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 15.67 M), actual EPS USD -0.0821 (forecast USD -0.008)

Mereo BioPharma Reports Q1 2025 Financials

Mereo Biopharma released FY2024 annual earnings on March 26 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2923 USD (forecast -0.0583 USD)

Mereo Biopharma released FY2024 Q4 earnings on March 26 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.0454 USD (forecast -0.0131 USD)

Mereo BioPharma Announces 2024 Financial Performance and Progress of setrusumab Phase 3 Study

Mereo Biopharma released FY2024 9 Months Earnings on November 12 (EST) with actual revenue of 0 and EPS of -0.2473

Mereo Biopharma released FY2024 Q3 earnings on November 12 (EST), with actual EPS -0.0973 (forecast -0.0186)

Mereo Biopharma Group PLC announces pricing of $50 million ADS direct offering at market price

Allbirds

Allied Gaming & ENT

Immutep

Hub Cyber Security

EUREKA ACQUISITION CORP COM USD0.0001 A (SUBS/RTS 03/07/2026)

Propanc Biopharma

Xanadu Quantum Tech - B

VisionSys AI

K-Tech Solutions

Ascent Solar Tech

Kiniksa Pharmaceuticals

MiMedx

Rigel制药

CapForce Inc.

福泰制药

再生元制药

Argenx

阿里拉姆制药

百济神州

Natera

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Mereo Biopharma(MREO.US)

Mereo Biopharma Stock Performance Chart